2024 AGENDA
| 6:00 – 9:30 PM | Registration | |
| 7:00 PM | Welcome Address | Dr. Christian Kollmannsberger, GUTG Chair |
| 7:10 – 9:30 PM | Welcome Dinner Reception | English Bay Room |
Saturday, April 20th, 2024
All Sessions Include 25% of Time for Question Periods and Audience Participation
| 7:00 – 8:00 AM | Breakfast | English Bay Room |
| 8:00 – 8:05 AM | Welcoming Remarks for Day 1 | Dr. Krista Noonan – GUTG Systemic Chair Grand Ballroom |
Prostate Session 1: Localized PC
Session Chairs: Dr. Cal Andreou, Dr. Ryan Urban
| 8:00 – 8:20 AM | Localized High Risk Prostate Cancer: Is There a Role for Neoadjuvant Treatment? | Dr. Miles Mannas |
| 8:20 – 8:40 AM | Panel: Multidisciplinary Care for High Risk Localized Prostate Cancer: Local Treatment and Adjuvant Therapy | Dr. Mira Keyes, Dr. Nathan Wong |
| 8:40 – 9:00 AM | Non-Metastatic Biochemical Recurrence After Local Therapy for Prostate Cancer: Novel Treatment Options and Multidisciplinary Care | Dr. Michael Peacock |
| 9:00 – 9:20 AM | Management of ARPis: Toxicity Management and Practical Application | Dr. Sunil Parimi |
| 9:20 – 9:40 AM | Genetic Testing in Prostate Cancer: Latest Updates | Dr. Alex Wyatt |
Special Session: Radiopharmaceutical Treatments for Prostate Cancer
Session Chairs: Dr. Param Bains, Dr. James Curtis, Dr. Stacy Miller
| 9:40 – 9:55 AM | PSMA PET: Indications and Future Use | Dr. Patrick Martineau |
| 9:55 – 10:10 AM | Delivery / Management – State of Affairs in BC | Dr. Don Wilson |
| 10:10 – 10:15 AM | Panel Discussion and Q&A Period | Dr. Patrick Martineau, Dr. Don Wilson |
| 10:15 – 10:30 AM | Health Break & Networking | English Bay Room |
RCC Session
Session Chairs: Dr. Soha Atallah, Dr. Samrad Ghavimi, Dr. Ed Hardy
| 10:35 – 10:55 AM | DEBATE: Adjuvant Pembro in High Risk RCC: Is There an Ideal Patient? – Yes, All Patients Should Be Treated – No, Only Selected Patients Should Be Treated |
Yes – Dr. Simon Yu No – Dr. Adam Fundytus |
| 10:55 – 11:15 AM | IO-Refractory RCC: Management Options | Dr. Aleksi Suo |
| 11:15 – 11:35 AM | Pathologic and Molecular Classification of RCC: Update on New Subtypes | Dr. Gang Wang |
| 11:35 – 11:55 AM | Hereditary Kidney Cancer Syndromes | Dr. Daniel Araujo |
| 11:55 – 12:15 PM | First Line Treatment of Non-Clear Cell RCC: Therapeutic Choices and Management | Dr. Daygen Finch |
| 12:15 – 1:00 PM | Lunch / Networking / Exhibition | English Bay Room |
| 1:00 – 1:20 PM | Special Session: Future of Cancer Care in BC | Dr. Kim Chi |
| 1:20 – 1:30 PM | Question & Answer Period |
Testis / Penile Cancer Session
Session Chairs: Dr. Iain McAuley, Dr. Jesse Shustik, Dr. Justin Owen
| 1:30 – 1:50 PM | Management of Postchemotherapy Residual Retroperitoneal / Retrocrural Masses in Germ Cell Cancer | Dr. Matthew Ho |
| 1:50 – 2:10 PM | Management of Postchemotherapy Residual Thoracic / Mediastinal Masses | Dr. Alexander Lee |
Penile Cancer
| 2:10 – 2:25 PM | Surgery | Dr. Nathan Wong |
| 2:25 – 2:40 PM | Advances in Radiotherapy for Penile Cancer | Dr. Juanita Crook |
| 2:40 – 2:55 PM | Medical Oncology | Dr. Michael Humphreys |
| 2:55 – 3:10 PM | Discussions | Dr. Nathan Wong, Dr. Juanita Crook, Dr. Michael Humphreys |
| 3:10 – 3:15 PM | Closing Remarks for Day 1 | Dr. Nathan Hoag, BCUS Chair |
| 7:00 PM – 9:30PM | BCGU Dinner Keynote: Artificial Intelligence & Medicine: Best Practices and Trustworthy Ecosystems Dr. Arman Rahmim, University of British Columbia |
Grand Ballroom |
Sunday, April 21st, 2024
All Sessions Include 25% of Time for Question Periods and Audience Participation
| 7:00 – 8:00 AM | Breakfast | English Bay Room |
| 8:00 – 8:05 AM | Welcoming Remarks for Day 2 | Dr. Jack Zheng – GURG RT Chair Grand Ballroom |
Bladder Cancer Session
Session Chairs: Dr. Alym Abdulla, Dr. Ardashes Avanessian, Dr. David Kim
| 8:05 – 8:25 AM | Non-Muscle Invasive Bladder Cancer: Are We Making Progress? | Dr. Brian Yang |
| 8:25 – 8:45 AM | PANEL: Bladder Preservation/Active Surveillance After Neoadjuvant Therapy in MIBC | Panelists: Dr. Marie-Pier St-Laurent & Dr. Clement Ho |
| 8:45 – 9:05 AM | DEBATE: EV-Pembro / Cis-Gem-Nivo as First Line Treatment for Cis-Eligible Patient: What is the Preferred Treatment for Cisplatin Eligible, Cisplatin-Ineligible and Platinum Ineligible?
– EV/Pembro for All |
EV/Pembro: Dr. Richard Gagnon Cis/Gem/Nivo: Dr. Susan Ellard |
| 9:05 – 9:25 AM | Later Line Treatment of Urothelial Cancer in an Evolving First-Line Landscape | Dr. Jean-Michel Lavoie |
| 9:25 – 9:45 AM | Is There a Role for Radiation in Oligometastatic / Locally Recurrent UC? | Dr. Tina Zhang |
| 9:45 – 10:05 AM | Appropriate Peri-Operative Systemic Treatment of Non-Urothelial Bladder Cancers | Dr. Bernie Eigl |
Special Session
Session Chair: Dr. Chris Hoag
| 10:05 – 10:25 AM | Surgical Quality Assurance for Cancer Care with an Emphasis on GU Cancers | Dr. Carl Brown |
| 10:25 – 10:50 AM | Health Break / Networking / Exhibition / Check-out |
English Bay Room |
Prostate Cancer Session 2: mCRPC
Session Chairs: Dr. Andrew Bang, Dr. Jaco Fourie, Dr. Jeffrey McCracken
| 10:50 – 11:10 AM | Targeting the AR in Metastatic PC: Is it Still a Target? | Dr. Lucia Nappi |
| 11:10 – 11:30 AM | mCRPC: Treatment Sequencing in the Era of Radioligand Therapies and PARP Inhibitor Combinations | Dr. Jasna Deluce |
| 11:30 – 11:50 AM | Metastatic Prostate Cancer: Novel Targets and Therapeutic Options on the Horizon | Dr. Corinne Maurice-Dror |
| 11:50 – 12:10 PM | Radiotherapy to Prostate in Metastatic Prostate Cancer | Dr. Hamid Raziee |
| 12:10 – 12:15 PM | BCGU Conference Closing Remarks | Dr. Christian Kollmannsberger, GUTG Chair |
Non-Accredited:
Special Session – GU Biobank
Session Chairs: Dr. Kim Chi, Dr. Corinne Maurice-Dror, Dr. Lucia Nappi, Dr. Alex Wyatt, Dr. Gillian Vandekerkhove
Grand Ballroom
| 12:30 – 12:40 PM | GUBB Introduction | GUBB Co-Directors: Dr. Corinne Maurice Dror & Dr. Gillian Vandekerkhove |
| 12:40 – 12:45 PM | Rolling Circle Amplification to Improve miR371 Detection in Patients with Early Stage GCT | Andy Jia |
| 12:45 – 12:50 PM | Biosensor Technology to Predict Tumor Recurrence in Patients With Early GCT | Dr. Sajjad Janfaza |
| 12:50 – 12:55 PM | Circulating miRNAs Analysis to Predict Immune Response in mRCC Patients | Dr. Guliz Ozgun |
| 12:55 – 1:00 PM | Prediction of Plasma ctDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer | Dr. Cameron Herberts |
| 1:00 – 1:05 PM | ctDNA-FGFR Status as a Predictive Biomarker for FGFR Targeted Therapy in Urothelial Cancer | Dr. Gillian Vanderkerkhove |
| 1:05 – 1:10 PM | The Prevalence of Clonal Hematopoiesis in Metastatic Genitourinary Cancers | Dr. Asli Munzur |
| 1:10 – 1:40 PM | Discussion and Future Directions | |
| 1:40 PM | Closing Remarks |